Preclinical data for Neovasc Inc.’s Tiara(TM) transcatheter mitral valve program to be presented at EuroPCR 2012

–Presentations will Highlight Promising Results from Animal Studies–

TSX Venture Exchange: NVC

VANCOUVER, May 14, 2012 /PRNewswire/ - Neovasc Inc. (TSXV: NVC), a developer of novel technologies to treat vascular
disease, today announced that its Tiara(TM) technology under development for the transcatheter treatment of mitral
valve disease will be featured in three scientific sessions at EuroPCR
2012, the annual meeting of the European Association for Percutaneous
Cardiovascular Interventions. In these sessions Dr. Shmuel Banai will
present data and several cases showing the successful implantation of
the Tiara device in acute animal models.

Neovasc CEO Alexei Marko commented, “We are making excellent progress in
the development of our Tiara technology for the transcatheter treatment
of mitral valve disease, and we are pleased to have the opportunity to
share our initial results in animals with leading interventional
cardiologists at EuroPCR.  With our strong background in vascular
device and tissue heart valve development and manufacture, we believe
we are well positioned to develop effective new therapies for this
challenging condition. While the Tiara program is early stage,
development work to date has yielded promising results, and we hope to
achieve the first implantations in humans in 2013.”

The Tiara program is a novel solution to treat mitral valve
regurgitation (MR), a serious and poorly served condition that requires
development of highly specialized devices to address the complex mitral
anatomy. The Tiara device is in preclinical development to provide a
minimally invasive transcatheter replacement procedure for the millions
of patients who experience MR.  Mitral regurgitation is often severe
and can lead to heart failure and death, but conventional surgical
treatments are only appropriate for a small percentage of patients.
Approximately four million patients in the US alone are estimated to
have MR.

Neovasc’s Tiara device will be featured in presentations at the
following EuroPCR 2012 sessions:

        --  Emerging technologies for transcatheter mitral valve therapies,
            May 16, 13:40-16:20pm,
            Room 252AB
        --  Best of Innovations in Cardiovascular Interventions
            Technoparade, May 17, 15:00-16:20pm,
            Room 351
        --  Novel approaches to percutaneous treatment of mitral
            regurgitation, May 18, 11:30am-12:50pm,
            Room 341.

Dr. Shmuel Banai, Medical Director of Neovasc, is an Associate Professor
of Medicine and Cardiology at the Tel Aviv University Sackler School of
Medicine and a Director of Interventional Cardiology at the Division of
Cardiology at the Tel Aviv Medical Center.

About EuroPCR

EuroPCR is the official congress of the European Association of
Percutaneous Cardiovascular Interventions (EAPCI) and is a leading
international meeting on the percutaneous treatment of cardiovascular
disease, attracting over 12,000 participants. EuroPCR 2012 is being
held in Paris, France May 15-18, 2012. For more information, visit www.europcr.com.

About Neovasc Inc.

Neovasc Inc. is a specialty medical device company that develops,
manufactures and markets products for the rapidly growing
cardiovascular marketplace. Its products include the Neovasc Reducer(TM)
for the treatment of refractory angina, the Tiara(TM) technology in
development for the transcatheter treatment of mitral valve disease and
a line of advanced biological tissue products that are used as key
components in a variety of third-party medical products, such as
vascular surgical patches and transcatheter heart valves. For more
information, visit: www.neovasc.com.

Statements contained herein that are not based on historical or current
fact, including without limitation statements containing the words
“anticipates,” “believes,” “may,” “continues,” “estimates,” “expects,”
and “will” and words of similar import, constitute “forward-looking
statements” within the meaning of the U.S. Private Securities
Litigation Reform Act of 1995. Such forward looking statements involve
known and unknown risks, uncertainties and other factors that may cause
the actual results, events or developments to be materially different
from any future results, events or developments expressed or implied by
such forward-looking statements. Such factors include, among others,
the following: general economic and business conditions, both
nationally and in the regions in which the Company operates; history of
losses and lack of and uncertainty of revenues, ability to obtain
required financing, receipt of regulatory approval of product
candidates, ability to properly integrate newly acquired businesses,
technology changes; competition; changes in business strategy or
development plans; the ability to attract and retain qualified
personnel; existing governmental regulations and changes in, or the
failure to comply with, governmental regulations; liability and other
claims asserted against the Company; and other factors referenced in
the Company’s filings with Canadian securities regulators. Although the
Company believes that expectations conveyed by the forward-looking
statements are reasonable based on the information available to it on
the date such statements were made, no assurances can be given as to
the future results, approvals or achievements. Given these
uncertainties, readers are cautioned not to place undue reliance on
such forward-looking statements. The Company does not assume the
obligation to update any forward-looking statements except as otherwise
required by applicable law.

SOURCE Neovasc Inc.